| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Revance Therapeutics, Inc. | Director | Common Stock | 29,722 | $222,023 | $7.47 | 04 May 2022 | Direct |
| AVROBIO, Inc. | Director | Stock Option (Right to Buy) | 17,643 | 06 Jun 2023 | Direct | ||
| Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 10,756 | 04 May 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TECX | AVROBIO, Inc. | 06 Jun 2023 | 1 | $0 | 4 | Director | 08 Jun 2023, 16:29 |
| TECX | AVROBIO, Inc. | 08 Jun 2022 | 2 | $0 | 4 | Director | 10 Jun 2022, 16:40 |
| /report/000147929022000068-vickers-philip-j-2022-05-04-restatement | Revance Therapeutics, Inc. | 04 May 2022 | 1 | $0 | 4/A | Director | 13 May 2022, 18:13 |
| TECX | AVROBIO, Inc. | 07 Jul 2021 | 1 | +$40,080 | 4 | Director | 08 Jul 2021, 16:21 |
| TECX | AVROBIO, Inc. | 10 Jun 2021 | 1 | $0 | 4 | Director | 14 Jun 2021, 17:51 |
| /report/000147929021000116-vickers-philip-j-2021-05-05 | Revance Therapeutics, Inc. | 05 May 2021 | 2 | $0 | 4 | Director | 07 May 2021, 19:15 |